Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: BGI, Agilent, ReadCoor, GeneNews

NEW YORK (GenomeWeb) – BGI confirmed this week that it has filed for an IPO on the ChiNext exchange, and is seeking to raise $250 million through the issuance of 40 million new shares. According to a Chinese media report, BGI recorded revenues of approximately $250 million and operating profit of about $55 million in 2016.

Agilent Technologies announced this week that its board has approved a quarterly dividend of $.13 per share of common stock to be paid on April 26 to all shareholders of record as of the close of business on April 4.

ReadCoor said this week that it has joined the Wyss Institute-led consortium seeking to map the brain's neural circuitry. The consortium has a $21 million contract from the Intelligence Advanced Research Projects Activity to discover the brain's learning rules and synaptic circuit design. ReadCoor will supply its FISSEQ (Fluorescent In-Situ Sequencing) platform, which the researchers will use to further their goal of mapping the brain's neuronal cell connections.

GeneNews said this week that it has inked an agreement with an undisclosed "large, multi-specialty physician group" in the American Midwest for use of its cancer diagnostic tests. It's the firm's second partnership agreement with a US healthcare services group, and it marks the introduction of its BreastSentry diagnostic test to the US market.

Patients of the medical group will have access to GeneNews' screening tests — ColonSentry, earlyCDT-Lung, Prostate Health Index, and BreastSentry — which provide early-risk stratification of colorectal cancer, lung cancer, prostate cancer, and breast cancer, respectively.

GeneNews will process the samples through its CAP- and CLIA-certified clinical reference laboratory in Richmond, Virginia.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.